Cite
Rosales M, Pérez GV, Ramón AC, et al. Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300. Biomedicines. 2021;9(7)doi: 10.3390/biomedicines9070766.
Rosales, M., Pérez, G. V., Ramón, A. C., Cruz, Y., Rodríguez-Ulloa, A., Besada, V., Ramos, Y., Vázquez-Blomquist, D., Caballero, E., Aguilar, D., González, L. J., Zettl, K., Wiśniewski, J. R., Yang, K., Perera, Y., & Perea, S. E. (2021). Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300. Biomedicines, 9(7), . https://doi.org/10.3390/biomedicines9070766
Rosales, Mauro, et al. "Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300." Biomedicines vol. 9,7 (2021). doi: https://doi.org/10.3390/biomedicines9070766
Rosales M, Pérez GV, Ramón AC, Cruz Y, Rodríguez-Ulloa A, Besada V, Ramos Y, Vázquez-Blomquist D, Caballero E, Aguilar D, González LJ, Zettl K, Wiśniewski JR, Yang K, Perera Y, Perea SE. Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300. Biomedicines. 2021 Jul 01;9(7). doi: 10.3390/biomedicines9070766. PMID: 34356831; PMCID: PMC8301452.
Copy
Download .nbib
